CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 165 enrolled
Drug / intervention
enVista MX60EFH trifocal intraocular lenses (IOLs) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04224155
NCT04224155N/ACompleted

A Prospective, Multicenter, Randomized, Masked, Controlled Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

Bausch & Lomb Incorporated·interventional·Posted Jan 13, 2020·Updated Oct 10, 2024

In Brief

A clinical study evaluating enVista MX60EFH trifocal intraocular lenses (IOLs) and enVista MX60E monofocal intraocular lenses (IOLs) for Cataract. Completed, enrolled 165 participants across 9 sites.

Detailed Summary

The objective of the study is to evaluate the safety and performance of the enVista trifocal intraocular lens when implanted in the capsular bag.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJan 13, 2020
Enrollment StartMar 10, 2020
Primary CompletionJun 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.5 years ago

Interventions

enVista MX60EFH trifocal intraocular lenses (IOLs)device

enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally

enVista MX60E monofocal intraocular lenses (IOLs)device

enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally